))
Leqembi: Five insights on the first fully approved Alzheimer's drug
Manage episode 371292259 series 2793637
Content provided by David E. Williams. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David E. Williams or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Leqembi was just approved to treat early stage Alzheimer's. In this solo episode, host David Williams shares five thoughts.
- Leqembi is just different enough from Aduhelm to survive scrutiny
- Patient registry requirement is a good idea
- The delivery system isn't ready
- Health equity will suffer
- Public health and prevention would be money better spent
Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.
193 episodes
Share
